Open an account

Dianthus Therapeutics

DNTH · NASDAQ

$78.75+$4.21 (+5.65%)TodayMarket closed ·
Prev close $74.54

About DNTH

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Employees
92
Headquarters
New York City, New York
Listed
Jun 21, 2018
Sector
Health Care
Industry
Biotechnology
Website
dianthustx.com

DNTH key statistics

Market cap
4.40B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
922.30K
Volume
1.87M
Open price
$74.61
High today
$79.93
Low today
$73.17
52 Week high
$117.88
52 Week low
$32.22

Dianthus Therapeutics (DNTH) at a glance

As of Oct 20, 2026, Dianthus Therapeutics (DNTH) shares are priced at $78.75, giving the company a market cap of 4.40B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $73.17 and $79.93. The current price is 7.6% above the day's low and 1.5% below its high.

Volume so far is 1.87M shares, above the average of 922.30K shares a day.

Over the past year Dianthus Therapeutics has ranged from $32.22 to $117.88, and now sits 54% of the way up that range.

Dianthus Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.90 per share against an estimate of -$0.8748.

The average analyst price target is $142.14, 80.5% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 14 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $142.14
Low
$123.22
Now
$78.75
High
$210.00

DNTH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 8.8% on average.

  1. Q3 FY24: reported -$0.74 per share against an estimate of -$0.6063
  2. Q4 FY24: reported -$0.81 per share against an estimate of -$0.8679
  3. Q1 FY25: reported -$0.82 per share against an estimate of -$0.866
  4. Q2 FY25: reported -$0.88 per share against an estimate of -$0.8891
  5. Q3 FY25: reported -$0.97 per share against an estimate of -$0.8796
  6. Q4 FY25: reported -$1.43 per share against an estimate of -$1.10
  7. Q1 FY26: reported -$0.85 per share against an estimate of -$1.09
  8. Q2 FY26: reported -$0.90 per share against an estimate of -$0.8748

DNTH news

  • Press releaseGlobe Newswire

    Dianthus Therapeutics to Participate in Three Investor Conferences During September

  • Vandana Singh

    Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

  • Vandana Singh

    Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

  • Press releaseGlobe Newswire

    Dianthus Therapeutics to Participate in Two Investor Conferences

  • Vandana Singh

    Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism

  • Press releaseGlobe Newswire

    Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

  • Press releaseGlobe Newswire

    Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

  • Press releaseGlobe Newswire

    Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Similar companies

Companies in the same industry as Dianthus Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.